🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

RecruitingNAAges 18 Years - anyAllChina Medical University, China
NCT07519837 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely id

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Signed informed consent form and voluntary participation in this study * Histologically and/or cytologically confirmed diagnosis of cancer * Patients with gastrointestinal malignancies, including: * Esophageal cancer * Hepatocellular carcinoma * Gastric cancer * Cholangiocarcinoma * Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy Exclusion Criteria: * Pregnant or lactating women * Presence of contraindications to surgery * Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate * Presence of two or more concurrent primary tumors
💊

What it tests

  • Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients
  • Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
  • Administration of placebo as a negative control to validate experimental efficacy
📍

Where

1 site
The First Affiliated Hospital of China Medical University
Shenyang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy